May 24, 2024 at 11:48AM
Cencora, a pharmaceutical services provider, suffered a data breach in February 2024 due to a cyberattack, compromising personal data of patients and medication information. This incident has affected major pharmaceutical companies in the US. Cencora has offered affected individuals two years of free identity protection and credit monitoring services. The investigation confirmed the exposed data does not appear to have been publicly disclosed or used for fraudulent purposes.
Based on the meeting notes, it’s clear that Cencora, formerly known as AmerisourceBergen, experienced a significant data breach in February 2024. The breach resulted in unauthorized access to the company’s information systems and the exfiltration of sensitive personal data.
The breach impacted several large pharmaceutical companies, leading to the exposure of individuals’ full names, addresses, health diagnoses, medications, and prescriptions. However, at this time, there is no evidence that the information has been publicly disclosed or used for fraudulent purposes.
In response to the breach, Cencora has initiated an internal investigation, which concluded on April 10, 2024. As a proactive measure, the company is offering affected individuals two years of free identity protection and credit monitoring services through Experian.
Despite the efforts to address the breach, limited additional information has been shared by Cencora, and the number of individuals impacted remains undisclosed. Furthermore, the California Attorney General’s office has received data breach notifications from the affected pharmaceutical firms, attributing the exposure of data to the Cencora incident.
This represents a significant breach of sensitive personal information within the pharmaceutical industry, and it is crucial for affected individuals and organizations to remain vigilant about potential risks and take advantage of the offered identity protection and credit monitoring services.
Please let me know if there are any specific actions or follow-ups you would like me to undertake based on this summary.